Accepting applications until August 1
Accepting applications until August 1
November McGarvey, Matthew Gitlin, Ela Fadli,and Karen C. Chung. BMC Health Services Research (2022) 22:1155
Cancer represents a significant source of disease burden in the United States (US), both clinically and economically. Diagnosis and treatment of cancer at earlier stages may reduce this burden. To better understand potential impac... Read More
C. Santucci, S. Mignozzi, M. Malvezzi, et al. Ann Oncol. 2024 Mar;35(3):308-316
We predicted cancer mortality figures for 2024 for the European Union (EU), its five most populous countries, and the UK. We predicted cancer mortality figures for 2024 for the European Union (EU), its five most populous countries... Read More
Xiang Li, Qiuyuan Li, Fujun Yang, et al. Ann Thorac Surg. 2025 Jun;119(6):1185-1195
This study was carried out to evaluate the impact of neoadjuvant therapy on long-term survival of patients with non-small cell lung cancer undergoing sleeve lobectomy. A total of 613 patients were retrospectively analyzed, includi... Read More
ML. Meyer, S. Peters, PA Jänne, TS Mok. Et al. ESMO Open. 2026 Feb;11(2):106034
Over the past decade, lung cancer management has been reshaped by advances in early detection, treatment, and prevention. Prevention now extends beyond tobacco control to include recognition of non-tobacco risk factors, screening,... Read More
Xin Zhang, Jing Zou, Jinghua Ning,et al. Sci Rep. 2025 Feb 20;15(1):6264
Tracheal, bronchial, and lung cancer (TBL) is among the most common malignancies worldwide, with persistently high incidence and mortality rates, posing a significant threat to public health. This study comprehensively evaluated t... Read More
Lanwei Guo, Chenxin Zhu, Lin Cai, et al. Lanwei Guo, Chenxin Zhu, Lin Cai, et al. Chinese Medical Journal 2024;137(21)
Lung cancer is the most common cancer and a leading cause of cancer-related deaths globally. The aim of this study was to evaluate the incidence and mortality of lung cancer worldwide in 2022 and to project the number of new cases... Read More
Yixin Zhou, Anlin Li, Hui Yu, et al. JAMA Netw Open. 2024 Mar 4;7(3):e241285
Neoadjuvant therapy combining programmed cell death 1 (PD-1) and programmed death ligand 1 (PD-L1) inhibitors with platinum-based chemotherapy has demonstrated significant improvement in pathologic response and survival rates amon... Read More
Douglas B. Johnson, Amin H. Nassar, Ayesha Aijaz,et al. Nat Rev Clin Oncol 2026 Feb 18.
Anti-PD-L1 antibodies have transformed cancer treatment and are increasingly being used in patients with early-stage malignancies including in the adjuvant and neoadjuvant settings. In this Review, we explore the optimal use of an... Read More
Allison W Kurian, Paul Abrahamse, Allison Furgal, et al. JAMA. 2023 Jul 3;330(1):43-51
Germline genetic testing is recommended by practice guidelines for patients diagnosed with cancer to enable genetically targeted treatment and identify relatives who may benefit from personalized cancer screening and prevention. A... Read More
Simiao Chen; Zhong Cao; Klaus Prettner; et al. JAMA Oncol. 2023;9(4):465-472
Cancers are a leading cause of mortality, accounting for nearly 10 million annual deaths worldwide, or 1 in 6 deaths. Cancers also negatively affect countries’ economicgrowth. This study estimated and projected the economic cost o... Read More
Wenxin Yan, Min Liu, Wenzhan Jing et al. Exp Hematol Oncol. 2025 Mar 17;14(1):38
The global cancer burden is rising, with early-onset cancers becoming more prevalent. We aimed to investigate the burden, trend and population disparity in 33 early-onset cancers from 2012 to 2021. In 2021, there were 2.65 mi... Read More
Rupayan Kundu, Ankush Mukhopadhyay, Niladri Kal, et al .JCO Glob Oncol 12, e2500170(2026). Volume 12
Early-onset cancer (EOC), defined as cancer occurring in individuals age 15-49 years, represents a growing global health burden. In 2021, there were approximately 23.6 million new EOC cases and 0.99 million deaths globally.... Read More